Sexual & Hormonal Health
Peptides for Testosterone Optimization: What the Evidence Shows
The peptides with real human evidence for raising or protecting endogenous testosterone are the classical reproductive gonadotropins — hCG and LH/FSH — not the boutique 'natural testosterone' research peptides. A ranked, evidence-graded review for 2026.
hCGKisspeptin-10GonadorelinLH / FSHHPG axis
The quick verdict
The peptides with real human evidence for raising or protecting endogenous testosterone are the classical reproductive gonadotropins — hCG and LH/FSH — not the boutique 'natural testosterone' research peptides. Here is the honest, evidence-graded ranking.
- Best overall
- hCG (Human Chorionic Gonadotropin) — The only agent here with a randomized trial proving it maintains intratesticular testosterone under full TRT suppression, plus FDA approval for male hypogonadotropic hypogonadism — the single best-evidenced endogenous-testosterone agent.
- Best value
- Gonadotropins (LH / FSH, hMG) — Approved biologics with Grade-A class evidence; where the goal is inducing spermatogenesis, FSH added to hCG is the established, label-supported male regimen rather than a boutique peptide.
- Best for Preserving fertility and testicular size while on testosterone replacement
- Low-dose hCG — RCT and cohort data show 250–500 IU every other day keeps intratesticular testosterone near or above baseline and preserves sperm parameters even under full axis suppression — the use case with the deepest human evidence.
How we evaluated
We ranked each agent strictly by the strength of HUMAN evidence for stimulating or preserving endogenous testosterone and supporting the hypothalamic-pituitary-gonadal (HPG) axis — not by popularity, marketing, or preclinical promise. Human RCTs and approved indications outrank mechanistic physiology studies, which outrank unstudied clinical extrapolation. We report dosing only as it appears in published trials and FDA labeling, and we separate human data from preclinical and anecdote at every step. This is informational and editorial content, not medical advice and not a sourcing or buying guide.
- Human evidence tier. RCT and FDA-approved indications rank highest; mechanistic human physiology next; unstudied clinical extrapolation lowest.
- Endpoint relevance. Weighted toward endpoints that matter for the axis — intratesticular testosterone, LH/FSH, spermatogenesis — not just a transient serum-testosterone bump.
- Regulatory & legal status. FDA approval, compounding eligibility, and 2026 anti-doping (WADA) status, verified against primary regulatory sources.
- Honesty of the claim. Whether the marketed use matches the evidence; we flag overclaims where popularity outruns data.
Rating scale: 1–5 stars, reflecting the strength and directness of HUMAN evidence for supporting endogenous testosterone / the HPG axis. Preclinical-only or unstudied uses are graded down regardless of popularity.
Last verified .
At a glance
| # | Name | Evidence | Rating | Best for | Pricing |
|---|---|---|---|---|---|
| 1 | hCG (Human Chorionic Gonadotropin) | A | 5.0 | Preserving intratesticular testosterone, testicular size and fertility during TRT, or restoring androgen production in hypogonadotropic hypogonadism | Prescription drug — varies by pharmacy/insurance |
| 2 | Gonadotropins (LH / FSH, hMG) | A | 4.5 | Inducing spermatogenesis in hypogonadotropic men (FSH added to hCG) and restoring a deficient axis with characterized, approved biologics | Prescription biologic — high cost, varies by pharmacy |
| 3 | Kisspeptin-10 (KP-10) | B | 2.5 | Understanding the upstream physiology of the axis and research contexts — not a real-world testosterone therapy | No legitimate channel — not approved or compoundable |
| 4 | Gonadorelin (synthetic GnRH/LHRH) | D | 2.0 | Pump-delivered axis restoration in diagnosed congenital hypogonadotropic hypogonadism — NOT as a proven hCG substitute on TRT | Prescription / compounded — varies by pharmacy |
| 5 | SERMs (Enclomiphene / Clomiphene) — the non-peptide comparator | B | 4.0 | Raising endogenous testosterone while preserving fertility in secondary hypogonadism — the strongest oral option, and a reason not to over-frame the problem as peptide-only | Prescription drug — varies by pharmacy/insurance |
hCG (Human Chorionic Gonadotropin)
The reference LH-mimetic — the single best-evidenced endogenous-testosterone agent
hCG is a placental glycoprotein hormone that acts as a high-affinity luteinizing-hormone mimetic at the LH/CG receptor on Leydig cells, directly driving testosterone — including the high intratesticular testosterone that serum levels do not reflect and that spermatogenesis depends on. It binds the receptor with roughly four to five times higher affinity than LH and lasts far longer (a 24–36 hour half-life versus minutes for LH), which is exactly why it became the practical LH replacement. The pivotal proof is a randomized, dose-ranging trial: 29 men on testosterone enanthate 200 mg/week (which crashed intratesticular testosterone by 94 percent) received concurrent hCG at 125, 250, or 500 IU every other day or placebo. Intratesticular testosterone rose linearly with dose, reaching about 26 percent above baseline at 500 IU. A retrospective series of hypogonadal men on TRT plus hCG showed serum testosterone rising from roughly 207 to 1,056 ng/dL with sperm preserved and no man becoming azoospermic. hCG is also FDA-approved for male hypogonadotropic hypogonadism. Strictly it is a hormone rather than a boutique peptide, but it earns the top rank on evidence alone.
Strengths
- Randomized dose-ranging trial proves it maintains intratesticular testosterone under full TRT suppression
- FDA-approved for male hypogonadotropic hypogonadism (an approved, label-supported indication)
- Cohort evidence shows preserved sperm parameters on TRT, with no azoospermia in one series
- Long half-life and high LHCGR affinity make it a practical, once-every-other-day LH replacement
Weaknesses
- Drives aromatization to estradiol — gynecomastia and fluid retention are common nuisances requiring E2 monitoring
- Compounded-hCG access is constrained after FDA bulk-substance policy changes, and OTC/'homeopathic' hCG is illegal
- Prohibited at all times in males under WADA S2.2.1; contraindicated in androgen-dependent malignancy
- Best for
- Preserving intratesticular testosterone, testicular size and fertility during TRT, or restoring androgen production in hypogonadotropic hypogonadism
- Pricing
- Prescription drug — varies by pharmacy/insurance
Gonadotropins (LH / FSH, hMG)
Approved biologics — the class that literally drives Leydig-cell testosterone and sperm production
This entry covers the injectable glycoprotein hormones themselves: recombinant FSH (follitropin alfa/beta, e.g. Gonal-f, Follistim), recombinant LH (lutropin alfa, Luveris), urinary FSH, and human menopausal gonadotropin (hMG, Menopur, which supplies both FSH and LH-activity). As a class, gonadotropins carry Grade-A evidence from large RCTs and a Cochrane meta-analysis of 42 trials across roughly 9,606 couples, though that body of evidence is dominated by female ovulation induction rather than male testosterone optimization. The direct relevance to endogenous male testosterone is mechanistic and firm: LH, or its hCG surrogate, is the hormone that drives Leydig-cell testosterone, and recombinant LH was RCT-validated to restore follicular function in profoundly LH-deficient patients, confirming exogenous LH is biologically active where the gonad can respond. For male axis restoration, FSH is FDA-approved for spermatogenesis induction when given with hCG, established in open-label trials of azoospermic hypogonadotropic men with spermatogenesis onset between 2.7 and 18 months — Grade B for that specific male indication. The physiology is the male analog of FSH-then-trigger: hCG or LH restores intratesticular testosterone first, then FSH completes sperm production. These are approved biologics, not research peptides.
Strengths
- Grade-A class evidence from large RCTs and a Cochrane meta-analysis (42 trials, ~9,606 couples)
- FDA-approved (FSH with hCG) for spermatogenesis induction in hypogonadotropic men
- LH directly drives Leydig-cell testosterone; recombinant LH is RCT-validated as biologically active
- Regulated, characterized biologics with defined potency — not gray-market research chemicals
Weaknesses
- The bulk of the Grade-A evidence is female fertility, not male testosterone optimization
- FSH alone does not raise testosterone — it must be paired with hCG/LH, and works only if the gonad can respond
- Injectable, expensive, and (for LH/hCG-active components) prohibited in males under WADA S2.2.1; not compoundable
- Best for
- Inducing spermatogenesis in hypogonadotropic men (FSH added to hCG) and restoring a deficient axis with characterized, approved biologics
- Pricing
- Prescription biologic — high cost, varies by pharmacy
Kisspeptin-10 (KP-10)
The most elegant lever, the weakest therapy — real physiology, no outcome trial, no legal channel
Kisspeptin-10 is the C-terminal decapeptide of kisspeptin, the master upstream activator of the axis; it binds KISS1R/GPR54 on GnRH neurons to trigger pulsatile GnRH and downstream LH and FSH. This is the only true boutique peptide in the ranking and, mechanistically, the most physiologically elegant lever because it stimulates the axis at its origin rather than bypassing it. Its physiological necessity is proven by nature: loss-of-function KISS1R mutations abolish puberty. The human data are solid but strictly mechanistic. In healthy men, an intravenous bolus at the optimal 1 µg/kg dose raised LH from about 4.1 to 12.4 IU/L within 30 minutes, and sustained infusion raised testosterone from 16.6 to 24.0 nmol/L while increasing LH pulse frequency without tachyphylaxis. That is genuine Grade-B human evidence that KP-10 raises endogenous testosterone acutely. But the gap between mechanism and therapy is large: there is no outcome RCT for treating hypogonadism or improving fertility, the roughly four-minute plasma half-life makes chronic outpatient dosing impractical, and the most advanced kisspeptin trials used the longer kisspeptin-54 isoform, not KP-10. When KP-10 was nominated to the FDA for secondary hypogonadism, the advisory committee voted against compounding inclusion in October 2024.
Strengths
- Solid Grade-B human physiology: raises LH and testosterone acutely in healthy men and increases LH pulse frequency
- Acts one step upstream of GnRH at the very origin of the axis — the most physiologically elegant mechanism here
- Notably well tolerated in trials, with 'no adverse events' reported across doses including a 22.5-hour infusion
Weaknesses
- No outcome RCT for treating hypogonadism or improving fertility — mechanism only
- Roughly four-minute half-life and solution instability make practical chronic dosing impractical
- Not FDA-approved and not compoundable after the Oct 2024 advisory-committee vote; sold only as a research chemical
- Prohibited at all times in males under WADA S2.2.1
- Best for
- Understanding the upstream physiology of the axis and research contexts — not a real-world testosterone therapy
- Pricing
- No legitimate channel — not approved or compoundable
Gonadorelin (synthetic GnRH/LHRH)
Proven by pump in CHH, unproven as the intermittent-SC TRT adjunct it's now sold as
Gonadorelin is synthetic native GnRH — the exact decapeptide the hypothalamus releases to drive pituitary LH and FSH. Its defining pharmacology is the pulsatility paradox: delivered in matching physiologic pulses it stimulates LH/FSH, but delivered continuously or over-frequently it desensitizes the receptor and collapses the axis, which is the basis of chemical castration. Gonadorelin has genuine Grade-B human efficacy when delivered as nature delivers GnRH — in pulses, by pump. In male congenital hypogonadotropic hypogonadism, pulsatile GnRH restored the axis (LH rose from 0.20 to 5.96 IU/L by six months with testosterone climbing toward normal), and a meta-analysis of seven studies and 420 patients found pulsatile GnRH gave earlier spermatogenesis and larger testes than gonadotropins. However — and this is the single most important honesty point — that evidence is for pump-delivered pulsatile therapy in diagnosed hypogonadotropic men, NOT for the intermittent subcutaneous injections of compounded gonadorelin that telehealth clinics now layer onto TRT. That contemporary use, the number-one reason gonadorelin is prescribed today, is a Grade-D extrapolation with no controlled-trial support. It rose to prominence chiefly because compounded hCG became hard to obtain, not because it outperforms hCG. Its one theoretical edge — that it also drives FSH — is plausible but unproven in this context.
Strengths
- Genuine Grade-B human efficacy as pulsatile-pump therapy in congenital hypogonadotropic hypogonadism
- Meta-analysis (7 studies, 420 patients) found pulsatile GnRH gave earlier spermatogenesis and larger testes than gonadotropins
- Legally compoundable (FDA 503A Category 1) and telehealth-prescribable, unlike kisspeptin-10
Weaknesses
- The popular intermittent-SC TRT-adjunct use is a Grade-D extrapolation with no controlled-trial support
- Intermittent (non-pulsatile) dosing may not reliably maintain intratesticular testosterone or sperm
- Over-frequent or continuous dosing desensitizes the very receptor it aims to stimulate
- Prohibited at all times in males under WADA S2.2.1; rare hypersensitivity/anaphylaxis after repeated dosing
- Best for
- Pump-delivered axis restoration in diagnosed congenital hypogonadotropic hypogonadism — NOT as a proven hCG substitute on TRT
- Pricing
- Prescription / compounded — varies by pharmacy
Source: Mao et al., Ann Transl Med 2021 (pulsatile GnRH in CHH)
SERMs (Enclomiphene / Clomiphene) — the non-peptide comparator
Included for honesty: the best-evidenced axis-stimulators that preserve fertility are small molecules, not peptides
This entry is deliberately not a peptide, and it belongs in any honest ranking of testosterone-optimization options because it is frequently the strongest tool. Selective estrogen receptor modulators (SERMs) — enclomiphene and clomiphene — are oral small molecules that block estrogen's negative feedback at the hypothalamus and pituitary. Removing that brake lifts endogenous LH and FSH, which drives the testis to make more of its own testosterone while keeping intratesticular testosterone and spermatogenesis intact. In practical terms this achieves the same goal as low-dose hCG — raising endogenous testosterone without shutting the axis off — but by mouth rather than by injection, and without the direct estradiol surge that LH/hCG-active agents produce. Because they preserve fertility and are oral, many clinicians prefer SERMs over injectable hCG when the explicit goal is maintaining sperm production, and enclomiphene in particular (the trans-isomer of clomiphene) has been studied specifically for raising testosterone in men with secondary hypogonadism. The reason to feature them here is corrective: a strictly peptide-only framing of testosterone optimization obscures the fact that the best-evidenced, most convenient axis-stimulating tools include non-peptides. They are not a substitute for clinician-ordered labs and monitoring, and they are not appropriate for a eugonadal man with a normal axis.
Strengths
- Oral, no injection required — a major convenience advantage over hCG and gonadotropins
- Raise endogenous LH/FSH and testosterone while preserving intratesticular testosterone and fertility
- No direct estradiol surge from an LH/hCG mechanism; often preferred when fertility is the explicit goal
- Enclomiphene has been studied specifically for testosterone in men with secondary hypogonadism
Weaknesses
- Not a peptide — included as the honest non-peptide comparator, not a 'testosterone peptide'
- Not evidenced to 'optimize' testosterone in a healthy man with a normal axis
- Clomiphene is a mix of isomers with variable estrogenic effects; visual/mood side effects reported in some men
- Still requires a clinician, labs and monitoring — not a self-administered protocol
- Best for
- Raising endogenous testosterone while preserving fertility in secondary hypogonadism — the strongest oral option, and a reason not to over-frame the problem as peptide-only
- Pricing
- Prescription drug — varies by pharmacy/insurance
Source: Crosnoe et al., Transl Androl Urol 2013 (SERMs vs hCG for fertility preservation)
Frequently asked
What is the single best-evidenced peptide for supporting endogenous testosterone?
hCG (human chorionic gonadotropin). A randomized, dose-ranging trial proved that low-dose hCG maintains intratesticular testosterone even under full testosterone-induced suppression, rising linearly with dose to roughly 26 percent above baseline at 500 IU every other day, and it is FDA-approved for male hypogonadotropic hypogonadism. Cohort data further show it preserves sperm parameters in men on testosterone replacement, with no man in one series becoming azoospermic. Strictly speaking hCG is a glycoprotein hormone rather than a boutique peptide, but it is the reference agent for endogenous-testosterone support and belongs at the top of any honest ranking.
Is gonadorelin as good as hCG for men on testosterone replacement therapy?
The evidence says no, or more precisely, it has never been tested head-to-head. Gonadorelin's genuine human efficacy is for pulsatile-pump therapy in congenital hypogonadotropic hypogonadism, where delivering GnRH in physiologic pulses restores the axis. The popular contemporary use, intermittent subcutaneous injections of compounded gonadorelin layered onto TRT, is a Grade-D extrapolation with no controlled-trial support. It became widely prescribed mainly because compounded hCG got harder to obtain after FDA enforcement. Pharmacologically, intermittent dosing may not reliably maintain intratesticular testosterone, and over-frequent or continuous dosing can desensitize the very receptor it aims to stimulate.
Does kisspeptin-10 raise testosterone, and can I get it?
In research settings, intravenous kisspeptin-10 reliably raises LH and testosterone in healthy men, with sustained infusion increasing testosterone from about 16.6 to 24.0 nmol/L while boosting LH pulse frequency. That is real Grade-B human physiology acting one step upstream of GnRH. However, there is no outcome trial showing it treats hypogonadism or improves fertility, its roughly four-minute half-life makes practical outpatient dosing impractical, and in October 2024 the FDA advisory committee voted against adding kisspeptin-10 to the compounding list. There is therefore no legitimate prescription or compounding channel; it is sold only as a research chemical not for human use.
Will these peptides raise testosterone in a healthy man with normal levels?
That is not what any of them is evidenced for. The human data all come from men with suppressed or deficient axes, such as TRT users or men with hypogonadotropic hypogonadism, not as boosters for normal physiology. In a healthy eugonadal man, the predictable effects of LH- or hCG-active agents are a rise in estradiol from aromatization and, with continuous dosing, desensitization of the axis. From a functional perspective, suppressed testosterone in an otherwise healthy man is usually downstream of correctable factors like poor sleep, excess body fat, alcohol, or overtraining, which are the durable levers rather than an injectable.
Are these agents legal to use, and are they banned in sport?
hCG and the gonadotropins are FDA-approved prescription drugs and biologics; gonadorelin acetate is legally compoundable under FDA's interim 503A Category 1 bulk lists and is telehealth-prescribable; kisspeptin-10 is not approved or compoundable after the 2024 advisory-committee vote. For athletes, the picture is strict: under the 2026 WADA Prohibited List, hCG, LH, GnRH/gonadorelin and kisspeptin are prohibited at all times in males under Section S2.2.1 because they raise endogenous testosterone. Exogenous FSH is not listed as ergogenic-prohibited because it does not raise testosterone directly. A male athlete needs a Therapeutic Use Exemption for any legitimate medical use.
Are there non-peptide options that beat these for raising testosterone while keeping fertility?
Yes, and honesty requires saying so. The best-evidenced oral agents for raising endogenous testosterone while preserving fertility are selective estrogen receptor modulators, or SERMs, specifically enclomiphene and clomiphene. These are small molecules, not peptides. They block estrogen's negative feedback at the hypothalamus and pituitary, which lifts LH and FSH and in turn drives the testis to make more of its own testosterone while keeping sperm production intact. Because they are oral and do not require injection, many clinicians prefer them over injectable hCG when fertility is the explicit goal, which is why a strictly peptide-only framing of testosterone optimization is somewhat artificial.